Linatab M Tablet 2.5 mg + 850 mg is a dual-action oral antidiabetic medication used to manage type 2 diabetes mellitus (T2DM) in adults. It combines Linagliptin, a DPP-4 inhibitor, with Metformin Hydrochloride, a biguanide, to provide complementary mechanisms for controlling blood glucose.

Linagliptin enhances glucose-dependent insulin secretion and reduces glucagon release, targeting postprandial hyperglycemia, while Metformin primarily lowers hepatic glucose production and improves insulin sensitivity. Together, Linatab M helps achieve better glycemic control, reduces HbA1c levels, and can support weight management without causing significant hypoglycemia when used appropriately.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Linagliptin: Dipeptidyl Peptidase-4 (DPP-4) inhibitor

• Metformin: Biguanide antidiabetic agent

• Overall Class: Combination oral antidiabetic therapy

Pharmacology

Linagliptin:
Linagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones like GLP-1 and GIP. By prolonging the activity of incretins, Linagliptin increases insulin secretion in a glucose-dependent manner and decreases glucagon secretion, reducing postprandial glucose spikes.

Metformin:
Metformin lowers blood glucose primarily by reducing hepatic gluconeogenesis, increasing peripheral glucose uptake, and improving insulin sensitivity. It also modestly decreases intestinal glucose absorption. Metformin is not associated with significant hypoglycemia when used as monotherapy.

Combination Effect:
Linatab M leverages the complementary actions of Linagliptin and Metformin to provide effective fasting and postprandial glucose control, with reduced risk of hypoglycemia and potential cardiovascular benefits.

Indications

Linatab M Tablet 2.5 mg + 850 mg is indicated for adults with type 2 diabetes mellitus:

• For glycemic control when diet and exercise alone are insufficient

• As an adjunct to other antidiabetic therapies

• For patients who require dual-action therapy targeting both fasting and postprandial blood sugar

Dosage and Administration

• Recommended dose: 1 tablet orally twice daily, preferably with meals to reduce gastrointestinal side effects

• Dose adjustment may be required for patients with renal impairment

• Patients should maintain adequate hydration and continue lifestyle modifications (diet, exercise)

Contraindications

• Type 1 diabetes mellitus

• Diabetic ketoacidosis

• Severe renal impairment or acute kidney injury

• Known hypersensitivity to Linagliptin, Metformin, or any excipients

• Acute or chronic metabolic acidosis

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Linatab M is generally well tolerated. Common side effects include:

• Gastrointestinal: nausea, vomiting, diarrhea, abdominal discomfort

• Respiratory: nasopharyngitis

• Rare: hypoglycemia (particularly if combined with sulfonylureas or insulin), lactic acidosis

Precautions and Warnings

• Monitor renal function regularly

• Discontinue Metformin temporarily during acute illness, dehydration, or contrast procedures

• Educate patients on recognizing signs of lactic acidosis (e.g., fatigue, muscle pain, rapid breathing)

Pregnancy and Lactation

• Linatab M is not recommended during pregnancy or breastfeeding

• Should only be used if potential benefits outweigh risks after careful medical assessment

Storage Conditions

Store in a cool, dry place below 30°C, protected from light and moisture. Keep out of reach of children.